摘要
目的:探讨拓扑替康为主的新辅助化疗和手术治疗小细胞肺癌的临床疗效及特点。方法:从2002年10月至2004年2月对16例小细胞肺癌患者进行术前化疗,拓扑替康1.5mg/(m·2d),连用5天,卡铂400mg/(m2·d),用1天,共化疗2个周期。休息4周后进行手术治疗。结果:化疗后疗效评价为完全缓解1例,部分缓解6例,好转6例,稳定2例,病变进展1例。临床缓解率为43.8%。2例全肺切除,14例肺叶切除加淋巴结清扫术。手术后1年生存率为75.0%,其中4例1年内死亡。结论:拓扑替康加卡铂新辅助化疗后,手术治疗的疗效优于单一方法治疗,患者可以耐受此方案化疗的不良反应,近期疗效肯定,为提高长期生存率提供了条件。
Objective： To explore the clinical curative effect and characteristics of small cell lung cancer （SCLC） in chemotherapy and operation. Methods： A total of 16 cases with SCLC were treated with Topotecan （TPT） and Carboplatin （CBP） before operation, TPT 1.5mg/m2/d from day 1 to day 5 and CBP400mg/m2/d at day 5. A Pneumonectomy or lobi-pulmonectomy and lymphoidectomy were completed, after 4 weeks of chemotherapy. Results： Clinical curative effect of the patients with chemotherapywas CR 1, PR 6, MR6, SD2 and PD1. Respite rate was 43.8%. The 1-year postoperative survival rate was 75.0%. Conclusions： The efficacy of chemotherapy in TPT and CBP, combined with the operation in treatment of SCLC, is better compared to any single therapy. The patients can tolerate the chemotherapy side-effects well. The treatment may bring about a better condition for a quite long survival time.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2005年第15期876-878,共3页
Chinese Journal of Clinical Oncology
